<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 07, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01206374</url>
  </required_header>
  <id_info>
    <org_study_id>10-027SLRHC</org_study_id>
    <nct_id>NCT01206374</nct_id>
  </id_info>
  <brief_title>Questionnaire and Laboratory Data on Vitiligo Vulgaris</brief_title>
  <official_title>Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin,
      hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that
      are thought to be required for development of vitiligo, only 5-10% of relatives develop
      disease. The triggers for disease onset have not yet been identified. The intent of this
      study is to research trends in laboratory data, social and medical history that may be
      contributory to vitiligo onset, location of disease, course of illness and response to
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who participate in this study will be asked to complete a survey and have blood/
      laboratory testing performed that relates or may relate to the diagnosis of vitiligo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Quality of life disturbances in people with vitiligo</measure>
    <time_frame>point prevalence</time_frame>
    <safety_issue>No</safety_issue>
    <description>dermatology life quality indices were you used and correlated with location of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>self-reporting of vitiligo disease symptoms and history</measure>
    <time_frame>single survey</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation of the patient survey response with chart documentation was performed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">57</enrollment>
  <condition>Vitiligo Vulgaris</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients willing to sign consent, complete questionnaire and/ or laboratory studies.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Vitiligo Vulgaris

          -  Ability to sign consent

        Exclusion Criteria:

          -  Pregnant

          -  Inability to sign consent

          -  Inability to complete questionnaire
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nanette Silverberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>StLukesNY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, St. Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Silverberg NB. Update on childhood vitiligo. Curr Opin Pediatr. 2010 Aug;22(4):445-52. doi: 10.1097/MOP.0b013e32833b6ac3. Review.</citation>
    <PMID>20616733</PMID>
  </reference>
  <reference>
    <citation>Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010 Jun;62(6):937-41. doi: 10.1016/j.jaad.2009.11.024.</citation>
    <PMID>20466170</PMID>
  </reference>
  <reference>
    <citation>Pagovich OE, Silverberg JI, Freilich E, Silverberg NB. Thyroid abnormalities in pediatric patients with vitiligo in New York City. Cutis. 2008 Jun;81(6):463-6.</citation>
    <PMID>18666385</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 22, 2015</lastchanged_date>
  <firstreceived_date>September 20, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo Vulgaris</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
